Skip to main content
Clinical Trials/ACTRN12608000304336
ACTRN12608000304336
Terminated
Phase 3

Feasibility and Safety of Dexmedetomidine Sedation for Patients presenting for Awake Fibreoptic Bronchoscopy

Keat Lee0 sites100 target enrollmentJune 20, 2008

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Safety and Feasibility of Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy
Sponsor
Keat Lee
Enrollment
100
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 20, 2008
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Keat Lee

Eligibility Criteria

Inclusion Criteria

  • 18 years and above, Presenting for awake fibreoptic bronchoscopy, and
  • Not pregnant at the start of the procedure/sedation

Exclusion Criteria

  • Allergy to dexmedetomidine,2nd degree heart block and above,Hypovolaemia,Hypotensive at the start of the procedure/sedation

Outcomes

Primary Outcomes

Not specified

Similar Trials